Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo.

ABSTRACT: PURPOSE:Molecular imaging techniques visualise biomarkers for both drug development and personalised medicine. In this field, Cherenkov luminescence imaging (CLI) seems to be very attractive by allowing imaging with clinical PET radiotracers with high-throughput capabilities. In this context, we developed a fast CLI method to detect tumour hypoxia with 18F-fluoromisonidazole (FMISO) for drug development purposes. METHODS:Colon cancer model was induced in mice by subcutaneous injection of 1 × 106 CT-26 cells. FMISO was injected, and simultaneous PET-blood oxygen level dependent (BOLD)-MRI followed by CLI were performed along with immunohistochemistry staining with pimonidazole. RESULTS:There was a significant correlation between FMISO PET and CLI tumour uptakes, consistent with the BOLD-MRI

SUBMITTER: Desvaux E 

PROVIDER: S-EPMC6301908 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature